Anjali Ganguli
Corporate Officer/Principal chez SYNDAX PHARMACEUTICALS, INC.
Postes actifs de Anjali Ganguli
Sociétés | Poste | Début | Fin |
---|---|---|---|
SYNDAX PHARMACEUTICALS, INC. | Corporate Officer/Principal | 01/05/2015 | - |
Historique de carrière de Anjali Ganguli
Anciens postes connus de Anjali Ganguli
Sociétés | Poste | Début | Fin |
---|---|---|---|
Regado Biosciences, Inc.
Regado Biosciences, Inc. Pharmaceuticals: MajorHealth Technology Regado Biosciences, Inc. is a biopharmaceutical company, which engages in the discovery and development of therapies in cardiovascular medicine using actively controlled aptamer technology. The company is focusing on new products for antithrombotic indications in the acute care and sub-acute care therapeutic setting. Its paired aptamer-active control agent technology is designed to give physicians the ability to directly control the degree of antithrombotic activity in real time on a "per patient, per setting" basis. The company's clinical programs are specifically concentrated on acute and sub-acute care injectable anticoagulants. Regado Biosciences was founded by Eli Gilboa, Bruce A. Sullenger and Christopher P. Rusconi on December 19, 2001 and is headquartered in Basking Ridge, NJ. | Corporate Officer/Principal | 01/02/2014 | 01/05/2015 |
Formation de Anjali Ganguli
University of Michigan | Doctorate Degree |
The University of Chicago | Undergraduate Degree |
Statistiques
Internationale
Etats-Unis | 5 |
Opérationnelle
Corporate Officer/Principal | 2 |
Doctorate Degree | 1 |
Undergraduate Degree | 1 |
Sectorielle
Health Technology | 3 |
Consumer Services | 3 |
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Sociétés liées
Sociétés cotées | 1 |
---|---|
SYNDAX PHARMACEUTICALS, INC. | Health Technology |
Entreprise privées | 1 |
---|---|
Regado Biosciences, Inc.
Regado Biosciences, Inc. Pharmaceuticals: MajorHealth Technology Regado Biosciences, Inc. is a biopharmaceutical company, which engages in the discovery and development of therapies in cardiovascular medicine using actively controlled aptamer technology. The company is focusing on new products for antithrombotic indications in the acute care and sub-acute care therapeutic setting. Its paired aptamer-active control agent technology is designed to give physicians the ability to directly control the degree of antithrombotic activity in real time on a "per patient, per setting" basis. The company's clinical programs are specifically concentrated on acute and sub-acute care injectable anticoagulants. Regado Biosciences was founded by Eli Gilboa, Bruce A. Sullenger and Christopher P. Rusconi on December 19, 2001 and is headquartered in Basking Ridge, NJ. | Health Technology |
- Bourse
- Insiders
- Anjali Ganguli
- Expérience